Jararhagin Disruption of Endothelial Cell Anchorage Is Enhanced in Collagen Enriched Matrices

Total Page:16

File Type:pdf, Size:1020Kb

Jararhagin Disruption of Endothelial Cell Anchorage Is Enhanced in Collagen Enriched Matrices Toxicon 108 (2015) 240e248 Contents lists available at ScienceDirect Toxicon journal homepage: www.elsevier.com/locate/toxicon Jararhagin disruption of endothelial cell anchorage is enhanced in collagen enriched matrices C. Baldo a, D.S. Lopes b, E.L. Faquim-Mauro a, J.F. Jacysyn c, S. Niland d, J.A. Eble d, * P.B. Clissa a, A.M. Moura-da-Silva a, a Laboratorio de Imunopatologia, Instituto Butantan, Av. Vital Brazil, 1500, 05503-900, Sao~ Paulo, SP, Brazil b Instituto de Genetica e Bioquímica, Universidade Federal de Uberlandia,^ Uberlandia,^ MG, Brazil c LIM62, Faculdade de Medicina da Universidade de Sao~ Paulo, Sao~ Paulo, SP, Brazil d Institute of Physiological Chemistry and Pathobiochemistry, University of Münster, 48149, Münster, Germany article info abstract Article history: Hemorrhage is one of the most striking effects of bites by viper snakes resulting in fast bleeding and Received 21 August 2015 ischemia in affected tissues. Snake venom metalloproteinases (SVMPs) are responsible for hemorrhagic Received in revised form activity, but the mechanisms involved in SVMP-induced hemorrhage are not entirely understood and the 19 October 2015 study of such mechanisms greatly depends on in vivo experiments. In vivo, hemorrhagic SVMPs accu- Accepted 27 October 2015 mulate on basement membrane (BM) of venules and capillary vessels allowing the hydrolysis of collagen Available online 31 October 2015 IV with consequent weakness and rupture of capillary walls. These effects are not reproducible in vitro with conventional endothelial cell cultures. In this study we used two-dimension (2D) or three- Keywords: Snake venom dimension (3D) cultures of HUVECs on matrigel and observed the same characteristics as in ex vivo Metalloproteinase experiments: only the hemorrhagic toxin was able to localize on surfaces or internalize endothelial cells Endothelial cell in 2D cultures or in the surface of tubules formed on 3D cultures. The contribution of matrigel, fibro- Extracellular matrix nectin and collagen matrices in jararhagin-induced endothelial cell damage was then analyzed. Collagen Hemorrhage and matrigel substrates enhanced the endothelial cell damage induced by jararhagin allowing toxin Collagen binding to focal adhesions, disruption of stress fibers, detachment and apoptosis. The higher affinity of jararhagin to collagen than to fibronectin explains the localization of the toxin within BM. Moreover, once located in BM, interactions of jararhagin with a2b1 integrin would favor its localization on focal adhesions, as observed in our study. The accumulation of toxin in focal adhesions, observed only in cells grown in collagen matrices, would explain the enhancement of cell damage in these matrices and reflects the actual interaction among toxin, endothelial cells and BM components that occurs in vivo and results in the hemorrhagic lesions induced by viper venoms. © 2015 Elsevier Ltd. All rights reserved. 1. Introduction hemorrhage that involves direct damage of microvessels (Baldo et al., 2010). Extracellular matrix (ECM) consists of a complex macromolec- Venom induced hemorrhage is a relevant symptom of enven- ular network responsible for tissue structural integrity and modu- omation with viper snakes and causes the massive local damage by lation of cellular activity. Collagens are the most abundant proteins disruption of capillary vessels. Consequently, blood leaks into tis- in the ECM. Collagen remodeling by matrix metalloproteinases sues and distal tissues become ischemic due to the lack of blood (MMPs) is commonly observed during normal tissue homeostasis. supply. Venom-induced hemorrhage has been attributed to the A rapid and extensive degradation of collagens is also detected in ability of snake venom metalloproteinases (SVMPs) to degrade some pathological situations, such as cancer, autoimmune diseases basement membrane (BM) components (Baramova et al., 1989; (Rosenblum et al., 2010), and on pathogenesis of venom-induced Escalante et al., 2006). However, different SVMPs are described and they vary considerably in hemorrhagic activity. PIII-class SVMPs are generally potent hemorrhagins while PI-class SVMPs present weak or undetectable hemorrhagic activity. Since both PI * Corresponding author. and PIII-SVMPs are equally able to degrade ECM components, the E-mail address: [email protected] (A.M. Moura-da-Silva). http://dx.doi.org/10.1016/j.toxicon.2015.10.016 0041-0101/© 2015 Elsevier Ltd. All rights reserved. C. Baldo et al. / Toxicon 108 (2015) 240e248 241 structural difference that could account for the hemorrhagic ac- previously described (Paine et al., 1992) with modifications tivity is the presence of additional adhesive domains, present only (Moura-da-Silva et al., 2003). BnP1 was purified from B. neuwiedi in PIII SVMPs, which could potentiate the catalytic action of the venom according to Baldo et al. (2008). The purity of toxins was toxins by binding to ECM or endothelial cells (Fox and Serrano, evaluated by SDS-PAGE 12.5%, under reducing conditions. Toxins ® 2005; Kamiguti et al., 1996; Tanjoni et al., 2010). This issue was were used in the native form or labeled with Alexa Fluor 488 investigated by our group comparing the mechanisms related to (Molecular Probes, USA) according to the manufacturer in- hemorrhagic activity of jararhagin, a well-known hemorrhagic PIII structions. BSA (Bovine serum albumin e Sigma Aldrich, USA) was SVMP isolated from Bothrops jararaca venom (Paine et al., 1992) and used as control of non-toxic protein in different sets of BnP1, a non-hemorrhagic PI SVMP isolated from Bothrops neuwiedi experiments. venom (Baldo et al., 2008). The results demonstrated that hemor- rhagic activity of jararhagin is correlated to its ability to bind to 2.2. Cell culture collagen (Baldo et al., 2010; Moura-da-Silva et al., 2008). In vivo, this toxin is able to selectively degrade the fibrillar collagen and base- HUVECs were harvested by type IV collagenase (Worthington, ment membrane collagen IV, co-localizing with the basement USA) digestion as described by Jaffe et al. (1973) and cultured on membrane of capillaries and venules on mouse skin (Baldo et al., gelatin-coated plastic dishes in RPMI 1640 medium supplemented 2010). On the other hand, BnP1 hydrolyzed ECM components with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 UI/mL in vitro (Baldo et al., 2008), but in vivo the toxin did not accumulate penicillin, 100 mg/mL streptomycin, 50 uM 2-mercaptoethanol, 5 U/ nearby blood vessels nor hydrolyzed BM collagens. These evidences mL heparin and 20 ng/mL bFGF. For bidimensional cultures (2D), 96 have been recently confirmed by Herrera et al., 2015 observing or 24 wells microplates were coated with type I collagen (BD tissue localization of two hemorrhagic SVMPs, CsH1 (PIII-SVMP Bioscience, USA), type IV collagen (BD Bioscience, USA), fibronectin from Crotalus simus) and BlatH1 (PII-SVMP from Bothriechis later- (Invitrogen, USA) or matrigel (Sigma Aldrich, USA) in a final con- alis), but not of BaP1, a weakly-hemorrhagic PI-SVMP from Bothrops centration of 50 mg/mL. Cells cultured on gelatin 1% or uncoated asper. In this sense, these observations strongly suggest the relevant plates were used as a control. For three-dimensional cultures (3D), role of interactions between adhesive domains present in the 30 mL of matrigel were added to a 24 well microplates containing toxins and BM components enhancing the proteolytic effect of glass coverslips (13 mm), following incubation of 30 min, 37 C. these enzymes, allowing disruption of microvessel walls. After that, 0.5 Â 105 cells were added on the top of gelled matrigel Endothelial cells are also essential for the integrity of micro- and cultured in the HUVECs medium for approximately 18 h, 37 C. vessels and the role of endothelial cells damage on hemorrhagic After that, the capillary-like structures could be observed. activity by PIII-SVMPs is another still open question. In vitro,both hemorrhagic and non-hemorrhagic SVMPs induce apoptosis of 2.3. Immunofluorescence assays endothelial cells at comparable levels (Diaz et al., 2005; Tanjoni et al., 2005). Additionally, hemorrhage induced by jararhagin Immunofluorescence experiments were carried out using in vivo occurs much faster than the apoptosis of endothelial cells markers for actin cytoskeleton (rhodamine-phalloidin), focal ad- in vitro, and apoptotic cells were not detected on hemorrhagic le- hesions (vinculin), and basement membrane (collagen IV and sions induced by SVMP from B. asper venom (Jimenez et al., 2008), laminin) as described below. In order to investigate the interaction ruling out that apoptosis of these cells is the prevalent mechanism of toxins with HUVECs, cells were treated with 800 nM Alexa Fluor for hemorrhages observed in vivo. However, apparently discrepant 488-labeled jararhagin (Alexa488-Jar), Alexa Fluor 488-labeled results obtained in vivo and in vitro may be due to the absence of BnP1 (Alexa488-BnP1) or Alexa Fluor 488-labeled BSA (Alexa488- experimental conditions that accurately model a complex micro- BSA) for 30 min. The samples were fixed in 3.7% formaldehyde environment observed in vivo. Most of these studies were per- for 10 min at room temperature. Nonspecific staining was blocked formed using endothelial cells grown on conventional culture by incubating the coverslips for 1 h at room temperature with a bottles, which are static and rigid surfaces. Therefore, they are very solution of Phosphate Buffer Saline (PBS) containing 1% triton X- distinct from the matrix microenvironment
Recommended publications
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Jararhagin ECD-Containing Disintegrin Domain: Expression in Escherichia Coli and Inhibition of the Platelet–Collagen Interaction
    Archives of Biochemistry and Biophysics Vol. 369, No. 2, September 15, pp. 295–301, 1999 Article ID abbi.1999.1372, available online at http://www.idealibrary.com on Jararhagin ECD-Containing Disintegrin Domain: Expression in Escherichia coli and Inhibition of the Platelet–Collagen Interaction Ana M. Moura-da-Silva,*,†,‡,1 Alex Lı´nica,* Maisa S. Della-Casa,* Aura S. Kamiguti,§ Paulo L. Ho,¶ Julian M. Crampton,† and R. David G. Theakston‡ *Laborato´rio de Imunopatologia and ¶Laborato´rio de Biotecnologia Molecular, Instituto Butantan, Av. Vital Brasil, 1500, 05503-900, Sa˜o Paulo, Brazil; §Department of Haematology, University of Liverpool, Prescot Street, Liverpool, L69 3BX, United Kingdom; and †Molecular Genetics Unit and ‡Alistair Reid Venom Research Unit, Liverpool School of Tropical Medicine, Pembroke Place, L3 5QA, Liverpool, United Kingdom Received May 17, 1999, and in revised form July 6, 1999 demonstrating that these antibodies recognize the Jararhagin, a hemorrhagin from Bothrops jararaca parent jararhagin molecule. Treatment of the fusion venom, is a soluble snake venom component compris- protein with enterokinase, followed by further cap- ing metalloproteinase and disintegrin cysteine-rich ture of the enzyme, resulted in a band of 30 kDa, the domains and, therefore, is structurally closely related expected size for jararhagin-C. Further purification of to the membrane-bound A Disintegrin And Metallo- the cleaved disintegrin using FPLC Mono-Q columns proteinase (ADAMs) protein family. Its hemorrhagic resulted in one fraction capable of efficiently inhibit- activity is associated with the effects of both metallo- ing collagen-induced platelet aggregation in a dose- proteinase and disintegrin domains; the metallopro- dependent manner (IC50 of 8.5 mg/ml).
    [Show full text]
  • Characterization of a Novel Metalloproteinase in Duvernoy's Gland of Rhabdophis Tigrinus Tigrinus
    The Journal of Toxicological Sciences, 157 Vol.31, No.2, 157-168, 2006 CHARACTERIZATION OF A NOVEL METALLOPROTEINASE IN DUVERNOY’S GLAND OF RHABDOPHIS TIGRINUS TIGRINUS Koji KOMORI1, Motomi KONISHI1, Yuji MARUTA1, Michihisa TORIBA2, Atsushi SAKAI2, Akira MATSUDA3, Takamitsu HORI3, Mitsuko NAKATANI4, Naoto MINAMINO4 and Toshifumi AKIZAWA1 1Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotogecho, Hirakata, Osaka 573-0101, Japan 2The Japan Snake Institute, 3318 Yabuzuka Ota, Gunma 379-2301, Japan 3Department of Biochemistry, Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan 4Department of Pharmacology, National Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan (Received January 31, 2006; Accepted February 20, 2006) ABSTRACT — During the characterization of hemorrhagic factor in venom of Rhabdophis tigrinus tigri- nus, so-called Yamakagashi in Japan, one of the Colubridae family, a novel metalloproteinase with molec- ular weight of 38 kDa in the Duvernoy’s gland of Yamakagashi was identified by gelatin zymography and by monitoring its proteolytic activity using a fluorescence peptide substrate, MOCAc-PLGLA2pr(Dnp)AR-NH2, which was developed for measuring the well-known matrix metalloproteinase (MMP) activity. After purification by gel filtration HPLC and/or column switch HPLC system consisting of an affin- ity column, which was immobilized with a synthetic BS-10 peptide (MQKPRCGVPD) originating from propeptide domain of MMP-7 and a reversed-phase column, the N-terminal amino acid sequence of the 38 kDa metalloproteinase was identified as FNTFPGDLK which shared a high homology to Xenopus MMP-9. The 38 kDa metalloproteinase required Zn2+ and Ca2+ ions for its proteolytic activity.
    [Show full text]
  • Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
    Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48
    [Show full text]
  • Structural, Functional and Therapeutic Aspects of Snake Venom Metal- Loproteinases
    Send Orders for Reprints to [email protected] 28 Mini-Reviews in Organic Chemistry, 2014, 11, 28-44 Structural, Functional and Therapeutic Aspects of Snake Venom Metal- loproteinases P. Chellapandi* Department of Bioinformatics, School of Life Sciences, Bharathidasan University, Tiruchirappalli-620024, Tamil Nadu, India Abstract: Snake venoms are rich sources of metalloproteinases that are of biological interest due to their diverse molecu- lar diversity and selective therapeutic applications. Snake venoms metalloproteinases (SVMPs) belong to the MEROPS peptidase family M12B or reprolysin subfamily, which are consisted of four major domains include a reprolysin catalytic domain, a disintegrin domain, a reprolysin family propeptide domain and a cysteine-rich domain. The appropriate struc- tural and massive sequences information have been available for SVMPs family of enzymes in the Protein Data Bank and National Center for Biotechnology Information, respectively. Functional essentiality of every domain and a crucial contri- bution of binding geometry, primary specificity site, and structural motifs have been studied in details, pointing the way for designing potential anti-coagulation, antitumor, anti-complementary and anti-inflammatory drugs or peptides. These enzymes have been reported to degrade fibrinogen, fibrin and collagens, and to prevent progression of clot formation. An- giotensin-converting enzyme activity, antibacterial properties, haemorrhagic activity and platelet aggregation response of SVMPs have been studied earlier. Structural information of these enzymes together with recombinant DNA technology would strongly promote the construction of many recombinant therapeutic peptides, particularly fibrinogenases and vac- cines. We have comprehensively reviewed the structure-function-evolution relationships of SVMPs family proteins and their advances in the promising target models for structure-based inhibitors and peptides design.
    [Show full text]
  • Albocollagenase, a Novel Recombinant P-III Snake Venom Metalloproteinase from Green Pit Viper (Cryptelytrops Albolabris), Digest
    Toxicon 57 (2011) 772–780 Contents lists available at ScienceDirect Toxicon journal homepage: www.elsevier.com/locate/toxicon Albocollagenase, a novel recombinant P-III snake venom metalloproteinase from green pit viper (Cryptelytrops albolabris), digests collagen and inhibits platelet aggregation Anuwat Pinyachat a,b, Ponlapat Rojnuckarin a,*, Chuanchom Muanpasitporn a, Pon Singhamatr a, Surang Nuchprayoon b a Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand b Department of Parasitology and Chulalongkorn Medical Research Center (Chula MRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand article info abstract Article history: Molecular cloning and functional characterization of P-III snake venom metalloproteinases Received 1 October 2010 (SVMPs) will give us deeper insights in the pathogenesis of viper bites. This may lead to Received in revised form 20 January 2011 novel therapy for venom-induced local tissue damages, the complication refractory to Accepted 9 February 2011 current antivenom. The aim of this study was to elucidate the in vitro activities of a new Available online 17 February 2011 SVMP from the green pit viper (GPV) using recombinant DNA technology. We report, here, a new cDNA clone from GPV (Cryptelytrops albolabris) venom glands encoding 614 amino Keywords: acid residues P-III SVMP, termed albocollagenase. The conceptually translated protein Green pit viper Albocollagenase comprised a signal peptide and prodomain, followed by a metalloproteinase domain Snake venom metalloproteinase (SVMP) containing a zinc-binding motifs, HEXGHXXGXXH-CIM and 9 cysteine residues. The dis- Cloning integrin-like and cysteine-rich domains possessed 24 cysteines and a DCD (Asp-Cys-Asp) Pichia motif. The albocollagenase deduced amino acid sequence alignments showed approxi- Collagen type IV mately 70% identity with other P-III SVMPs.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan Et Al
    US 2004.008 1648A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan et al. (43) Pub. Date: Apr. 29, 2004 (54) ADZYMES AND USES THEREOF Publication Classification (76) Inventors: Noubar B. Afeyan, Lexington, MA (51) Int. Cl." ............................. A61K 38/48; C12N 9/64 (US); Frank D. Lee, Chestnut Hill, MA (52) U.S. Cl. ......................................... 424/94.63; 435/226 (US); Gordon G. Wong, Brookline, MA (US); Ruchira Das Gupta, Auburndale, MA (US); Brian Baynes, (57) ABSTRACT Somerville, MA (US) Disclosed is a family of novel protein constructs, useful as Correspondence Address: drugs and for other purposes, termed “adzymes, comprising ROPES & GRAY LLP an address moiety and a catalytic domain. In Some types of disclosed adzymes, the address binds with a binding site on ONE INTERNATIONAL PLACE or in functional proximity to a targeted biomolecule, e.g., an BOSTON, MA 02110-2624 (US) extracellular targeted biomolecule, and is disposed adjacent (21) Appl. No.: 10/650,592 the catalytic domain So that its affinity Serves to confer a new Specificity to the catalytic domain by increasing the effective (22) Filed: Aug. 27, 2003 local concentration of the target in the vicinity of the catalytic domain. The present invention also provides phar Related U.S. Application Data maceutical compositions comprising these adzymes, meth ods of making adzymes, DNA's encoding adzymes or parts (60) Provisional application No. 60/406,517, filed on Aug. thereof, and methods of using adzymes, Such as for treating 27, 2002. Provisional application No. 60/423,754, human Subjects Suffering from a disease, Such as a disease filed on Nov.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • SIFTS: Updated Structure Integration with Function, Taxonomy and Sequences Resource Allows 40-Fold Increase in Coverage of Struc
    D482–D489 Nucleic Acids Research, 2019, Vol. 47, Database issue Published online 16 November 2018 doi: 10.1093/nar/gky1114 SIFTS: updated Structure Integration with Function, Taxonomy and Sequences resource allows 40-fold increase in coverage of structure-based annotations for proteins Jose M. Dana1, Aleksandras Gutmanas 1, Nidhi Tyagi2, Guoying Qi2, Claire O’Donovan3, Maria Martin2 and Sameer Velankar1,* 1Protein Data Bank in Europe, European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK, 2Protein Function Development, European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK and 3Metabolomics, European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK Received September 07, 2018; Revised October 15, 2018; Editorial Decision October 18, 2018; Accepted October 22, 2018 ABSTRACT source for sequence and functional information pertain- ing to proteins (1). It currently contains over 500 000 The Structure Integration with Function, Taxonomy manually annotated sequences (UniProtKB/Swiss-Prot) and Sequences resource (SIFTS; http://pdbe.org/ and over 120 million computationally annotated ones sifts/) was established in 2002 and continues to oper- (UniProtKB/TrEMBL) despite a near 50% reduction of the ate as a collaboration between the Protein Data Bank size of the holdings in 2015 to remove high sequence re- in Europe (PDBe; http://pdbe.org) and the UniProt dundancy. This increase is set to continue and likely to ac- Knowledgebase (UniProtKB; http://uniprot.org). The celerate even further with the growing appreciation of the resource is instrumental in the transfer of anno- role microbiome plays in health and disease.
    [Show full text]
  • Petri Nykvist Integrins As Cellular Receptors for Fibril-Forming And
    Copyright © , by University of Jyväskylä ABSTRACT Nykvist, Petri Integrins as cellular receptors for fibril-forming and transmembrane collagens Jyväskylä: University of Jyväskylä, 2004, 127 p. (Jyväskylä Studies in Biological and Environmental Science, ISSN 1456-9701; 137) ISBN 951-39-1773-8 Yhteenveto: Integriinit reseptoreina fibrillaarisille ja transmembraanisille kollageeneille Diss. The two integrin-type collagen receptors α1β1 and α2β1 integrins are structurally very similar. However, cells can concomitantly express both receptors and it has been shown that these collagen receptor integrins have distinct signaling functions, and their binding to collagen may lead to opposite cellular responses. In this study, fibrillar collagen types, I, II, III, and V, and network like structure forming collagen type IV tested were recognized by both integrins at least at the αI domain level. The αI domain recognition does not always lead for cell spreading behavior. In addition transmembrane collagen type XIII was studied. CHO-α1β1 cells could spread on recombinant human collagen type XIII, unlike CHO-α2β1 cells. This finding was supported by αI domain binding studies. The results indicate, that α1β1 and α2β1 integrins do have different ligand binding specificities and distinct collagen recognition mechanisms. A common structural feature in the collagen binding αI domains is the presence of an extra helix, named helix αC. A αC helix deletion reduced affinity for collagen type I when compared to wild-type α2I domain, which indicated the importance of helix αC in collagen type I binding. Further, point mutations in amino acids Asp219, Asp259, Asp292 and Glu299 resulted in weakened affinity for collagen type I. Cells expressing double mutated α2Asp219/Asp292 integrin subunit showed remarkably slower spreading on collagen type I, while spreading on collagen type IV was not affected.
    [Show full text]
  • Crystal Structure Analysis of a Snake Venom Metalloproteinase In
    Crystal structure analysis of a snake venom metalloproteinase in complex with an inhibitor as basis for considerations on the proteolytic activity and the hemorrhagic mode of action INAUGURALDISSERTATION zur Erlangung der Doktorwürde der Fakultät für Chemie, Pharmazie und Geowissenschaften Albert-Ludwigs Universität Freiburg im Breisgau vorgelegt von Torsten Jens Lingott aus Bayreuth Freiburg im Breisgau November 2010 Tag der Bekanntgabe des Prüfungsergebnisses: 16.12.2010 Dekan: Prof. Dr. H. Hillebrecht Referentin: Prof. Dr. I. Merfort Korreferent: Prof. Dr. J. M. Gutiérrez Drittprüfer: Prof. Dr. A. Bechthold Parts of this thesis have been or are prepared to be published in the following articles: Lingott, T., Schleberger, C., Gutiérrez, J. M., and Merfort, I. (2009). High-resolution crystal structure of the snake venom metalloproteinase BaP1 complexed with a peptidomimetic: insight into inhibitor binding. Biochemistry 48 , 6166-6174. Wallnoefer, H. G., Lingott, T., Gutiérrez, J. M., Merfort, I., and Liedl, K. R. (2010). Backbone flexibility controls the activity and specificity of a protein-protein interface: Specificity in snake venom metalloproteases. J Am Chem Soc 132 , 10330-10337. Lingott, T. and Merfort, I. (xxxx). The catalytic domain of snake venom metalloproteinases - Sequential and structural considerations. in preparation. Wallnoefer, H. G.*, Lingott, T.*, Escalante, T., Ferreira, R. N., Nagem, R. A. P., Gutiérrez, J. M., Merfort, I., and Liedl, K. R. (xxxx). The hemorrhagic activity of P-I snake venom metalloproteinases
    [Show full text]
  • Disintegrins from Snake Venoms and Their Applications in Cancer Research and Therapy
    Send Orders for Reprints to [email protected] 532 Current Protein and Peptide Science, 2015, 16, 532-548 Disintegrins from Snake Venoms and their Applications in Cancer Research and Therapy Jéssica Kele Arruda Macêdo1,2,3, Jay W. Fox3,* and Mariana de Souza Castro1,2 1Brazilian Center for Protein Research, Department of Cell Biology, Institute of Biology, University of Brasília, Brasília/DF, Brazil; 2Toxinology Laboratory, Department of Physiological Sciences, Institute of Biology, University of Brasília, Brasília/DF, Brazil; 3Department of Microbiology, Immunology and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA, USA Abstract: Integrins regulate diverse functions in cancer pathology and in tumor cell development and contribute to important processes such as cell shape, survival, proliferation, transcription, angiogene- sis, migration, and invasion. A number of snake venom proteins have the ability to interact with in- tegrins. Among these are the disintegrins, a family of small, non-enzymatic, and cysteine-rich proteins found in the venom of numerous snake families. The venom proteins may have a potential role in terms of novel therapeutic leads for cancer treatment. Disintegrin can target specific integrins and as such it is conceivable that they could interfere in important processes involved in carcinogenesis, tumor growth, invasion and migration. Herein we present a survey of studies involving the use of snake venom disintegrins for cancer detection and treatment. The aim of this review is to highlight the relationship of integrins with cancer and to present examples as to how certain disin- tegrins can detect and affect biological processes related to cancer. This in turn will illustrate the great potential of these molecules for cancer research.
    [Show full text]